Comparative Pharmacology
Head-to-head clinical analysis: DALFAMPRIDINE versus RUZURGI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DALFAMPRIDINE versus RUZURGI.
DALFAMPRIDINE vs RUZURGI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium channel blocker that enhances neuronal transmission by prolonging repolarization and increasing neurotransmitter release in demyelinated neurons.
Amifampridine blocks voltage-gated potassium channels, thereby prolonging the action potential duration and increasing calcium influx at the nerve terminal. This enhances acetylcholine release at the neuromuscular junction, improving muscle strength.
10 mg orally twice daily, 12 hours apart.
32 mg orally three times daily (total daily dose 96 mg), to be taken with food.
None Documented
None Documented
5-6 hours in patients with normal renal function; prolonged to 15-20 hours in moderate renal impairment.
Clinical Note
moderateDalfampridine + Clotrimazole
"The metabolism of Clotrimazole can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Ticlopidine
"The metabolism of Ticlopidine can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Nicotine
"The metabolism of Nicotine can be decreased when combined with Dalfampridine."
Clinical Note
moderateDalfampridine + Quinidine
Terminal elimination half-life is approximately 4.5 hours (range 3.5–5.5 h), supporting twice-daily dosing.
Renal excretion of unchanged drug (95%); fecal (<5%).
Primarily renal excretion of unchanged drug (~60%) with minor fecal elimination (~30%); <10% metabolized.
Category C
Category C
Potassium Channel Blocker
Potassium Channel Blocker
"The serum concentration of Quinidine can be increased when it is combined with Dalfampridine."